Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chaiqin Tonglin tablets for recurrent urinary tract infections (Phase II dose-finding, randomized, double-blind, placebo-controlled)
ChiCTR2400087723Phase 2Recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Aug 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Chaiqin Tonglin tablets in urinary tract infection (UTI) and bacterial cystitis (3 arms), sponsored by Guang'anmen Hospital. Primary endpoints: Clinical recurrence rate / average recurrence frequency during the whole study period, Urine bacteriology positive recurrence rate / average recurrence frequency during the whole study period and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
Chaiqin Tonglin tablets
03
Conditions
urinary tract infection (UTI)bacterial cystitis
Beyond the preview
Go deeper on ChiCTR2400087723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087723.